GlassScriptPhysician profile
Haroon S Hyder
NPI 1740470483
$2,116.58
in general payments reported to CMS, 2019-2025
33 companies · $34.64 in 2025
The $34.64 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $86.76 · 2021: $482 · 2022: $578 · 2023: $427 · 2024: $117 · 2025: $34.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $559.32 | 2021-2023 | |
| Novo Nordisk INC | $315.79 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $173.98 | 2019-2022 | |
| Amgen INC. | $133.80 | 2019-2023 | Evenity, Prolia |
| Medtronic, INC. | $104.35 | 2022 | |
| Neurelis, INC. | $97.83 | 2024 | Valtoco |
| Bayer Healthcare Pharmaceuticals INC. | $81.64 | 2021-2023 | |
| Lilly USA, LLC | $78.81 | 2019-2023 | Trulicity, Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $62.01 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $44.06 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.39 | 2021 | |
| Janssen Pharmaceuticals, INC | $35.59 | 2019-2021 | |
| Inspire Medical Systems, INC. | $33.50 | 2024-2025 | Inspire |
| Edwards Lifesciences Corporation | $29.37 | 2022-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Merck Sharp & Dohme LLC | $28.51 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $26.28 | 2019 | |
| Mylan Specialty L.P. | $25.94 | 2021 | |
| Sanofi Pasteur INC. | $24.37 | 2019 | |
| Impulse Dynamics (USA) INC. | $23.49 | 2023 | Optimizer |
| Abbott Laboratories | $19.93 | 2025 | Proclaim |
| Glaxosmithkline, LLC. | $19.09 | 2023 | Shingrix, Arexvy |
| Pfizer INC. | $16.87 | 2023 | |
| Alexion Pharmaceuticals, INC. | $16.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.39 | 2021 | |
| Currax Pharmaceuticals LLC | $14.43 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.65 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.15 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.87 | 2019 | |
| Grifols USA, LLC | $12.42 | 2021 | |
| Clarus Therapeutics INC. | $11.75 | 2021 | |
| Genentech USA, INC. | $11.66 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.51 | 2020 | |
| Allergan, INC. | $11.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haroon Hyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.